Tailoring mTOR-based therapy: molecular evidence and clinical challenges. - Wikidata - awgldk - TriplyDB

Tailoring mTOR-based therapy: molecular evidence and clinical challenges.

Tailoring mTOR-based therapy: molecular evidence and clinical challenges.

http://www.wikidata.org/entity/Q34294170

about

Sirolimus and Everolimus Pathway: Reviewing Candidate Genes Influencing Their Intracellular Effects Is There Any Significant Difference in Stent Thrombosis Between Sirolimus and Paclitaxel Eluting Stents?: A Systematic Review and Meta-Analysis of Randomized Controlled Trials The two faces of miR-29 Proteotoxicity: an underappreciated pathology in cardiac disease WORMHOLE: Novel Least Diverged Ortholog Prediction through Machine Learning Angiopoietin-Like Proteins: A Comprehensive Look An activator of mTOR inhibits oxLDL-induced autophagy and apoptosis in vascular endothelial cells and restricts atherosclerosis in apolipoprotein E⁻/⁻ mice.A selective microRNA-based strategy inhibits restenosis while preserving endothelial function.microRNAs Distinctively Regulate Vascular Smooth Muscle and Endothelial Cells: Functional Implications in Angiogenesis, Atherosclerosis, and In-Stent Restenosis.Sevoflurane postconditioning protects rat hearts against ischemia-reperfusion injury via the activation of PI3K/AKT/mTOR signaling Functional role of Calstabin2 in age-related cardiac alterations.Intravitreal sirolimus for the treatment of geographic atrophy: results of a phase I/II clinical trial Association of bone loss with the upregulation of survival-related genes and concomitant downregulation of Mammalian target of rapamycin and osteoblast differentiation-related genes in the peripheral blood of late postmenopausal osteoporotic women.Tuberous Sclerosis: A New Frontier in Targeted Treatment of Autism 18α-Glycyrrhetinic Acid Induces Apoptosis of HL-60 Human Leukemia Cells through Caspases- and Mitochondria-Dependent Signaling Pathways.Models for preclinical studies in aging-related disorders: One is not for all.Mechanistic Role of MicroRNAs in Coupling Lipid Metabolism and Atherosclerosis.Physical activity ameliorates cardiovascular health in elderly subjects: the functional role of the β adrenergic system.Downregulation of p70S6K Enhances Cell Sensitivity to Rapamycin in Esophageal Squamous Cell Carcinoma Atrial fibrillation and microRNAs.Functional role of miRNA in cardiac resynchronization therapy.L-Leucine and NO-mediated cardiovascular function.Potential therapeutic effects of mTOR inhibition in atherosclerosis.Targeting mTOR for the treatment of B cell malignancies.Bioresorbable Scaffolds for Atheroregression: Understanding of Transient Scaffolding Exploiting the potential of autophagy in cisplatin therapy: A new strategy to overcome resistance.GDF11 Protects against Endothelial Injury and Reduces Atherosclerotic Lesion Formation in Apolipoprotein E-Null Mice.Tyrosine-Kinase Inhibitors Therapies with Mainly Anti-Angiogenic Activity in Advanced Renal Cell Carcinoma: Value of PET/CT in Response Evaluation.Construction of competitive endogenous RNA network reveals regulatory role of long non-coding RNAs in type 2 diabetes mellitus.Small-molecule RL71-triggered excessive autophagic cell death as a potential therapeutic strategy in triple-negative breast cancer.Sirolimus induces depletion of intracellular calcium stores and mitochondrial dysfunction in pancreatic beta cells.Inhibition of 5-Hydroxytryptamine Receptor 2B Reduced Vascular Restenosis and Mitigated the β-Arrestin2-Mammalian Target of Rapamycin/p70S6K Pathway.Intracellular calcium release channels: an update.Ryanodine Receptor Structure and Function in Health and Disease.Bioactive components and mechanisms of Chinese poplar propolis alleviates oxidized low-density lipoprotein-induced endothelial cells injury.Clinical analysis of lectin-like oxidized low-density lipoprotein receptor-1 in patients with in-stent restenosis after percutaneous coronary intervention.

P2860

Q26749011-C3F6C9E9-5B46-462E-BC67-05CC46FB4EBF Q26769033-C8F5BE6C-88D8-473F-8D4F-1719141F35F3 Q26996481-814B7DFC-7960-4438-8201-9954793C60D4 Q28304890-76B59D50-8ADA-4C54-B508-D758338191FA Q28822241-461CAC02-B8BF-4C68-8B09-814052E04F45 Q29395294-0FC63CE6-B8EE-4D42-A6EB-6E43AFA405BC Q33827198-DAF1E887-17B2-4A4A-BD1D-D23F464071CA Q34129012-B277C654-A3D6-4B92-89BC-9A8E12657CE8 Q34504964-2CF23AEE-28EF-4CB9-A909-173362C40474 Q34628699-F08007A0-33E0-4576-902E-91DB3FD60860 Q34675791-75DF6789-23EA-4A65-9C25-AE01DF18D85B Q34956193-529F7492-9B71-4774-A9FB-98276EF7B51E Q35113761-BAFCB7AD-AAC0-463D-ADF8-F6AA90D230B3 Q35811772-B2324C3A-2B5D-49AE-8E4C-3F7880E591F0 Q36067419-FC901028-DEF3-4FEE-949A-B028893481E2 Q36738466-892F7A06-25BA-48C7-A99E-5FAF3E0EC0A3 Q36912465-0D73C4D0-6D21-4BAB-B5A9-041F480D2ED8 Q37086960-E15D0B10-C1B6-4DCA-A98E-DBD380BB2A89 Q37195321-DC6DD469-1C56-4B82-9B95-652D14821B3B Q37511368-CF649B6A-4A11-4A27-8E55-EC6D53AF33DD Q38236031-C61ACDFD-E705-4B50-B968-B076CEEEA42C Q38304866-D1A55ABC-F3E6-40A8-946C-DCAFCE26BA95 Q38628797-BF1FB93B-965B-46BD-9371-2C6DB15664E0 Q38709825-88B06D2A-B802-4FDA-B36B-516B798556C6 Q38714351-7237B48B-CEF8-4B89-8CFE-BEFB711EBD6F Q38868212-560C62AC-0103-4DA1-A99D-8A79E6AC1B81 Q40630512-C343EA66-9787-4EEE-85BD-1CABFCD9ED27 Q41660750-C218E899-59D0-4DDA-BFE3-3D0E6AA046C8 Q42018263-439BD4D8-A75A-4D5F-91BA-CFD2DA5DBD02 Q42261432-9863CB1A-F9E9-4ED0-90C0-E10B4C3D9ABB Q45018173-38E71C3E-BFC8-4B7A-8BD7-BD05D39D070C Q47639140-6D7BE224-07EB-4499-AC32-5243649A701D Q48112565-26DCFB42-8F2E-49E1-91EC-0CF969206F4E Q49721336-19C004CD-E78C-46D3-BC30-01021CF9C871 Q54979811-76365996-7C0E-4A5C-96C7-6B83BE6D96EB Q55387317-D24D4A16-324B-4B5C-B558-FD49F68401D1

P2860

Tailoring mTOR-based therapy: molecular evidence and clinical challenges.

http://www.wikidata.org/entity/Q34294170

description

2013 nî lūn-bûn

@nan

2013 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Tailoring mTOR-based therapy: molecular evidence and clinical challenges.

@ast

Tailoring mTOR-based therapy: molecular evidence and clinical challenges.

@en

Tailoring mTOR-based therapy: molecular evidence and clinical challenges.

@nl

type

label

Tailoring mTOR-based therapy: molecular evidence and clinical challenges.

@ast

Tailoring mTOR-based therapy: molecular evidence and clinical challenges.

@en

Tailoring mTOR-based therapy: molecular evidence and clinical challenges.

@nl

prefLabel

Tailoring mTOR-based therapy: molecular evidence and clinical challenges.

@ast

Tailoring mTOR-based therapy: molecular evidence and clinical challenges.

@en

Tailoring mTOR-based therapy: molecular evidence and clinical challenges.

@nl

P1433

Q34294170-68CA1B46-D7E0-45D1-806E-CB8489495D91

P1476

Q34294170-076CF52A-AAAD-43E4-A562-14010D557AFA

P2093

Q34294170-364A45E8-7D26-4783-8413-BB45B2582F24

P2860

Q34294170-0024319D-DC87-4FAA-BF98-B4D786181A60

Q34294170-01C3647B-0BDD-4851-B523-BF55485052CF

Q34294170-069F234B-F3F6-4901-8F05-52B8AA9B2252

Q34294170-085C4DA2-8D50-424E-B8BE-78A2E022E12D

Q34294170-0AB23694-2F02-4E83-9F0D-34C83146E40B

Q34294170-0EAEA311-2C19-4D74-A29E-31ED87571C0D

Q34294170-14656E84-D623-4581-ADA7-F9806A2943C4

Q34294170-173A816B-9D38-4454-A8D0-B958CB45D682

Q34294170-17843BC4-F355-49CA-9183-C2D39E219AF9

Q34294170-1811E592-5E7E-4726-B40D-5C34E9281817

P304

Q34294170-E90F9097-8446-4C29-97F5-E35E0B4EDB4C

P31

Q34294170-341F72B8-B9FF-451B-A75E-7E42E0096D6A

P356

Q34294170-55D9B656-4941-41C9-A27B-BB6E019AC3FC

P433

Q34294170-7FEB3A20-F503-4635-AB64-16CCEABCCCE3

P478

Q34294170-92159A1F-FA5C-4D98-A9BF-491B6BD033C9

P50

Q34294170-8490EBDF-8CDF-40E5-887F-8E5154EEE72F

P577

Q34294170-9C3DFD30-13C7-4A1E-BBD4-42F185864BCB

P5875

Q34294170-FDA9B768-4FE6-48C7-B3D3-FB1CC7F608B0

P698

Q34294170-B8939CA4-895B-4783-A247-B49C5A838F6D

P932

Q34294170-2173F04A-82DF-4268-9B36-89B6A938C881

P356

P1433

Pharmacogenomics

P1476

Tailoring mTOR-based therapy: molecular evidence and clinical challenges.

@en

P2093

Gaetano Santulli

http://www.w3.org/2001/XMLSchema#string

P2860

PI3K/AKT/mTOR Pathway in Angiogenesis

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus

mTOR signaling in growth control and disease

Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndrome

A complex interplay between Akt, TSC2 and the two mTOR complexes

MicroRNAs in stress signaling and human disease

Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

Rapamycin sensitivity in Saccharomyces cerevisiae is mediated by a peptidyl-prolyl cis-trans isomerase related to human FK506-binding protein

P304

1517-1526

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/PGS.13.143

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P50

Hana Totary-Jain

P577

2013-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

256499012

http://www.w3.org/2001/XMLSchema#string

P698

24024901

http://www.w3.org/2001/XMLSchema#string

P932

4186793

http://www.w3.org/2001/XMLSchema#string